About omacetaxine
Protein synthesis inhibitor anticancer medicine
Used for
- Treats chronic-phase or accelerated-phase chronic myeloid leukemia resistant to or intolerant of multiple tyrosine kinase inhibitors.
Usual adult dose
1.25 mg/m² injected under the skin twice daily for 14 days per 28-day cycle initially; later cycles may use 7 days.
Common side effects
- Low blood counts, including infection risk, anemia, and bleeding
- Diarrhea, nausea, vomiting, or constipation
- Fatigue, weakness, or fever
- Injection-site reactions
Important warnings
- Can cause severe bone-marrow suppression, infection, or bleeding.
- May cause high blood sugar; monitor glucose, especially with diabetes.
- Avoid pregnancy; treatment can harm an unborn baby.
- Administered by injection under the skin, not intravenously.
Pregnancy
Can harm an unborn baby. Effective contraception is advised during treatment and for six months afterward for women, and three months for men.
Breastfeeding
Breastfeeding is not recommended during treatment and for two weeks after the last dose.
Interactions
- Medicines that affect blood clotting may increase bleeding risk.
- Medicines that lower blood counts may increase bone-marrow suppression.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.